Aprogen's subsidiary issues 50.8B won CB to repay affiliate debt, risks 93% dilution of subsidiary shares
Aprogen's subsidiary Aprogen Biologics decided to issue 50.8B KRW in 20th series unregistered private convertible bonds. Conversion price is 3,778 won, potentially issuing 13,446,267 shares (93.3% of current outstanding), raising significant dilution risk for subsidiary equity.
Proceeds will be used to fully repay 50.8B KRW in loans to affiliate (주)앱토크롬, which is 52.28% owned by Aprogen.
Bond terms: coupon 2%, yield to maturity 4%, maturity June 23, 2029. Put option exercisable from 1.5 years after issuance, every 3 months.
Combined with existing convertible bonds (128B KRW), total convertible potential reaches 178.8B KRW, convertible into 37,873,359 shares, or 262.78% of current shares, amplifying dilution overhang.
[AI Summary]This CB issuance aims to improve the subsidiary's financial structure, but the conversion price is not deeply discounted relative to current market price (3,778 vs 3,610 won), and funds are solely for debt repayment rather than growth investment. The 93% dilution at subsidiary level may negatively impact Aprogen's equity method valuation, posing additional shareholder value erosion risk.
KOSPI Filing Information
Filing: [Correction of Description] Report On Major Matters (Decision On Issuance Of Convertible Bonds) (Major Management Matters Of Subsidiary)